ET

Syra Health Announces First Quarter 2024 Financial Results, Led By Strong Revenue Growth of 47%.

Retrieved on: 
Jeudi, mai 9, 2024
Table, Public, GAAP, Administration, Population health, Investment, Office of Refugee Resettlement, Conference call, Washington, D.C., Health education, Family, Hand, Depression, Growth, IPO, Digital health, Benchmarking, Mental health, Prevalence, Interest

CARMEL, Ind., May 9, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), ("Syra Health" or the "Company") a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, announced today its financial results for the first quarter ended March 31, 2024.

Key Points: 
  • The Company anticipates full-year 2024 revenue of $9 to $11 million, representing growth of 64%-100% versus 2023.
  • Announced a one-year, $480,000 contract from the Indiana Department of Health to administer public health and healthcare readiness assessments.
  • Our growth remains strong in our newest business units of Digital Health and Health Education, and we are excited that our Healthcare Workforce business unit has returned to growth in 2024.
  • Revenue for the quarter ended March 31, 2024, was $1.7 million, compared to the $1.2 million reported in the first quarter of 2023.

EQS-News: Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Vendredi, mai 10, 2024
Janus, Use, Research and development, Calcium, PMS, SPMS, German, Investment, AFL, Research, Webcast, Expense, Administration, Patent, RMS, Treatment, Patient, Psoriasis, Clinical trial, Biotechnology, Sirtuin 6, Pharmaceutical industry

January 2024: Announced a three-tranche private placement totaling up to $240 million, with participation from select new and existing investors.

Key Points: 
  • January 2024: Announced a three-tranche private placement totaling up to $240 million, with participation from select new and existing investors.
  • With these funds, Immunic expects to be able to fund its operations into the third quarter of 2025.
  • Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.
  • An archived replay of the webcast will be available approximately one hour after completion on Immunic’s website at: ir.imux.com/events-and-presentations .

Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Jeudi, mai 9, 2024
DAS, AMD, Boehringer Ingelheim, Research, Johnson & Johnson, Conference, Webcast, Conference call, Patient, M&A, CPT, Eye, Pharming, Conditional sentence, Data analysis, MBA, Drug delivery, Clinical trial, Biotechnology, ARVO, Visual acuity, Pharmaceutical industry

ALPHARETTA, Ga., May 09, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • ET -
    ALPHARETTA, Ga., May 09, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
  • License and other revenue for the first quarter of 2024 was $230,000, compared to $4,000 for the first quarter of 2023.
  • Other expense for the first quarter of 2024 was $1.5 million, compared to $0 for the first quarter of 2023.
  • Clearside’s management will host a webcast and conference call today at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update

Retrieved on: 
Jeudi, mai 9, 2024
FDA, Investment, Connective tissue, Food, Research, Diabetes, Weight loss, Attention, Obesity, Three Months, Fibrosis, Webcast

GAITHERSBURG, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • Cash, cash equivalents and short-term investments of $182.1 million at March 31, 2024
    Webcast to be held today, May 9, 2024, at 8:30 am ET
    GAITHERSBURG, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.
  • With these promising data, we are preparing for our End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), which is expected to occur late in the third quarter.
  • Financial Results for the Three Months Ended March 31, 2024
    Altimmune had cash, cash equivalents and short-term investments totaling $182.1 million at March 31, 2024.
  • Research and development expenses were $21.5 million for the three months ended March 31, 2024, compared to $17.2 million in the same period in 2023.

Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference

Retrieved on: 
Jeudi, mai 9, 2024
Citizenship, Therapy, Patient, Conference, Webcast

WARREN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in The Citizens JMP Life Sciences Conference on May 13, 2024.

Key Points: 
  • WARREN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in The Citizens JMP Life Sciences Conference on May 13, 2024.
  • The Aquestive management team will hold a fireside chat on May 13 at 11:30 am ET and will host investor meetings.
  • A webcast of the fireside chat will be available on the "Events and Presentation" page of the Investors section of the Company's website.
  • A replay of the webcast will be available for 30 days following the event.

Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Jeudi, mai 9, 2024
Conditional sentence, Research, Insurance, Conference, Conference call, Patent, Disease, BHC, Toxicology, Therapy, Fibromyalgia, Valaciclovir, Celecoxib, Famciclovir, Pharmaceutical industry

ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.

Key Points: 
  • ET -
    ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.
  • General and administrative expenses for the first quarter of 2024 were $1.0 million, compared to $1.1 million for the first quarter of 2023.
  • The quarter over quarter change was primarily due to a decrease in insurance expenses associated with being a public company.
  • The Company believes it will have sufficient resources to fund operations into the fourth quarter of 2024.

ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event

Retrieved on: 
Mardi, mai 7, 2024
Chicago Medical School, Itch, University, Patient, Skin, MD, Doctor of Philosophy, KOL, Potential, Week, Data, University of Rochester, Physician, Magnetic resonance, Atopic dermatitis, ASLN, Clutch (eggs), SAN, Pharmaceutical industry

“The numbers we have reported from the interim analysis of the TREK-DX study are unprecedented in previous biologics studies in atopic dermatitis (AD) and the new data continue to support our original conclusions announced in April.

Key Points: 
  • “The numbers we have reported from the interim analysis of the TREK-DX study are unprecedented in previous biologics studies in atopic dermatitis (AD) and the new data continue to support our original conclusions announced in April.
  • During the KOL event today, Company management will present new data on investigator-assessed and patient-reported secondary endpoints and data from the subgroup of patients with prior inadequate response to dupilumab.
  • Discontinuation rates were lower for patients treated with eblasakimab (13%, 2/15) compared to those on placebo (43%, 3/7).
  • Waterfall plots of individual patient responses show clear and consistent improvements in almost all patients treated with eblasakimab versus placebo.

Arbutus to Participate in Two Upcoming Investor Conferences

Retrieved on: 
Mardi, mai 7, 2024
CFBV, Arbutus, Webcast, The Citizen, Citizenship, Virology, Conference, Fireside chats

WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York:

Key Points: 
  • WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York:
    The Citizens JMP Life Sciences Conference: Fireside Chat on May 14, 2024 at 9:30 am ET
    H.C. Wainwright 2nd Annual BioConnect Investor Conference: Fireside Chat on May 20, 2024 at 3:30 pm ET
    To access the live webcast of the fireside chats please visit: https://investor.arbutusbio.com/events-presentations .
  • An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.

Pediatrix Medical Group Reports First Quarter Results

Retrieved on: 
Mardi, mai 7, 2024
Health, Consumer, Hospitals, Women, Practice Management, Baby, Maternity, General Health, Debt-to-GDP ratio, Acquisition, Webcast, Depreciation, Public expenditure, Adjustment, Tax, GAAP, Physician, EPS

Investment and other income was $2.0 million for the first quarter of 2024, compared to $0.6 million for the first quarter of 2023.

Key Points: 
  • Investment and other income was $2.0 million for the first quarter of 2024, compared to $0.6 million for the first quarter of 2023.
  • Interest expense was $10.6 million for the first quarter of 2024 compared to $10.4 million for the first quarter of 2023.
  • For the first quarter of 2024, Pediatrix reported Adjusted EPS of $0.20, compared to $0.23 for the first quarter of 2023.
  • For the first quarter of 2024, Pediatrix used cash of $122.6 million to fund continuing operations, compared to a use of $100.6 million during the first quarter of 2023.

Fuel Tech Reports 2024 First Quarter Financial Results

Retrieved on: 
Mardi, mai 7, 2024
Utilities, Oil, Gas, Sustainability, Environment, Energy, Engineering, Green Technology, Manufacturing, CHEM, Investment, Weather, Aquaculture, DGI, Coal, Upcoming, APC, Adjustment, FUEL, Interest, Security (finance)

Fuel Tech, Inc. (NASDAQ: FTEK), a technology company providing advanced engineering for the optimization of combustion systems, emissions control, and water treatment in utility and industrial applications, today reported financial results for the first quarter (Q1 2024) ended March 31, 2024.

Key Points: 
  • Fuel Tech, Inc. (NASDAQ: FTEK), a technology company providing advanced engineering for the optimization of combustion systems, emissions control, and water treatment in utility and industrial applications, today reported financial results for the first quarter (Q1 2024) ended March 31, 2024.
  • We are currently pursuing additional FUEL CHEM opportunities at units that use coal and other fuel sources, which could provide incremental revenue contribution in the latter half of 2024.
  • Adjusted EBITDA loss was $(1.5) million in Q1 2024 compared to Adjusted EBITDA loss of $(0.6) million in Q1 2023.
  • Management will host a conference call on Wednesday, May 8, 2024 at 10:00 am ET / 9:00 am CT to discuss the results and business activities.